风湿病的免疫及生物治疗进展.pdf

Chinese Journal of New Drues 2001 Vol 10 No 7
中国新志2001年第10卷第7期
参考文献
pondylitis J J. Rheum afol, 1998, 25(4)714-717
I] Calin A, Plswood J, Rigg S, er al. Ankylosing spondylitis: an
1 1 Braun Bollow M, Neure T , er al. [se of immuno histologic and
analytical Teview of 1500 patients: the changing pattern of the
in situ hybridization techniqucs in the examination of sacroiliac
diseasc J l.Jrheumalo/,1988, 15(8)-1234-1238
joint biopsy Specimens from patients with ankylosing spondylitis
[2] (ran J T, Skomsvll F. The outcome of ankylosing spondylitis: a
LJ」. A ruhr/ is Rheum、,1995,38(4)499-505
study of 100 paticntslj I Br Rheum atol, 1997, 36(7):766
「121(i
I, Collado A, Filella X, et a1. Serum cytokines (li
INI-0, IL-1B and LIN-I)in ankylosing spondylitis: a close cor-
13 I Clegy DO, Reda DJ, Abdcllatif M. Comparison of sulfasalazine
relation between serum Il-6 and di sease activity and severity
and placebo for the treat ment of axlal and perip heral articular
I]. Br Rheum al01, 1994, 33(10)327-931
manifestations of seronegative spondylart hropalhicslj l. Arthri-
[131 Brandt ], Haibel H, Cornely D, et al. Successful treatment of ac-
tis Rheum,1999,42(11)2.325-2329.
tive ankylosing spondylitis with the anti-tumor necrosis [actor a
14 I loussirol I, Wendling D. Current guidelines for the drug trcal
clonal antibody infl ximab J Arthritis Rheum, 2000, 43
ment of ankylosing spondylitis []. Drugs, 1998, 56(2):225
14 Van Der RP, Kruithof F, Baeten D, et al. Fffects of a loading
5] Van Der T S, Van Der HID. Ankylo sing spondylitis. Clinical fea-
dosc regimen of three in! usions of chimeric monoclonal antibody
tures J I. Rheum Dis Clin North Am
1998,24(4)663-67
necrosis a (infliximab in spondylart hropathy: an open pilot
16 Maugars Y, Mat his C, Bert helot M, et al. Assessment of the ef-
sludyuj 1 A nn Rhenm Dis, 2000, 59(6)428-433
ficacy of sacroiliac corticosteroid injcctions in spondyart hropat hies: a /151 Breban M, (mbet B, mor B, er al. Ficacy of thalidomide in
double blind study [J]. Br J Rheum atol, 1996, 35(8):767
the trcat ment of refractory ankylosing spondylitis J I. d rthritis
Rheum,1999,42(3)580-581
[7] Dougados M, Behier J Jolchine I, et al. Ffficacy of celecoxib, a
116 luang I Gu J Braun J, et a/. Identifying the targets of thalido
COX-2 specilic inhibitor in the trealment of ankylosing spondyl
mide and antr- TN Fa antibody treat ments in ankylosing spondyl
tisuj]A ,thritis Rheum, 2001, 44(1):180-185
lisl J.4rhrilis Rheum, 2000, 43(9)396
l8」BisD, Carlctto A, Caamaschi P,eo. Efficacy of methotrexate「17黄烽,赵伟.反应停对强直性脊柱炎治疗作用的初步观察
LA」.首届华夏风湿性病诊断治疗学术会议论文汇編LC
in the treatment of ankylosing spondylitis: a three year open
上海:中华医学会风湿病学会,19990123
sludy J Clin Rheum ato1, 2000,19(2)114-117
9 Sampaio BP Costallat T, TT. Bertolo M.et al. Met hotrexate in
118 Koh WII, Pande 1, Samucls A, e/ al. Low dose amiriptyline in
the trcal ment of ankylosing spondylilisuj I. Scand J Rheum aol
ankylosing spondylitis: a short term, double blind, placebo con-
2000,29(3):160-16
trolled sludylj |. Rheumatol, 1997, 24(11) 2158-2161
110] Maka ymowych WP J hangri GS, Leclercq S,e/ a/. An open study
(收稿期:2001-05-14
风湿病的免疫及生物治疗进展
栗占国
(北京大学人民医院风況免疫科,北京100044)
[摘要]免疫及生物治疗是风